Risk Factors for Gemcitabine-Induced Vascular Pain in Patients With Pancreatic Cancer
| Autor: | Kojiro Hata, Toshikazu Tsuji, Kimitaka Suetsugu, Kohei Nakata, Munehiko Ikeda, Hiroyuki Watanabe, Mio Ikebe, Takafumi Nakashima, Haruna Minami, Yoko Makihara, Ichiro Ieiri, Hitomi Watanabe, Shigeru Ishida, Kenichiro Nagata, Masafumi Nakamura, Nobuaki Egashira |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty Peripheral intravenous Pain Deoxycytidine 03 medical and health sciences 0302 clinical medicine Risk Factors Internal medicine Pancreatic cancer Antineoplastic Combined Chemotherapy Protocols medicine Humans Pharmacology (medical) In patient 030212 general & internal medicine Retrospective Studies Hot pack business.industry medicine.disease Gemcitabine Pancreatic Neoplasms Vascular pain 030220 oncology & carcinogenesis business medicine.drug |
| Zdroj: | The Annals of pharmacotherapy. 55(6) |
| ISSN: | 1542-6270 |
| Popis: | Background: Peripheral intravenous injection of gemcitabine often causes vascular pain; however, preventive measures have not yet been established. Objectives: This study focused on identifying predictive factors for gemcitabine-induced vascular pain. Methods: We retrospectively analyzed risk factors for developing vascular pain in patients with pancreatic cancer receiving gemcitabine infusions at our institution. Infusions were divided into groups according to presence or absence of vascular pain symptoms, and variables were compared. Odds ratios for risk factors were calculated using logistic regression analyses. Results: Overall, 272 patients with pancreatic cancer were subjected to 725 gemcitabine infusions, and of these, 18.4% (n = 50) experienced vascular pain. There were significant differences in the gemcitabine dose ( P = 0.025), dose of gemcitabine/body surface area (BSA; P = 0.004), concentration of gemcitabine ( P = 0.025), and hot pack use ( P = 0.011) between the vascular pain and no vascular pain groups. Multivariable analyses indicated that gemcitabine dose/BSA and lack of hot pack use were risk factors for developing vascular pain. Moreover, on administration of a higher dosage (>930 mg/m2), the incidence of vascular pain in patients using a hot pack (6.7%) was significantly lower than that in patients not provided a hot pack (16.2%). Conclusions and Relevance: High gemcitabine dosages and lack of hot pack use were predictive factors for gemcitabine-induced vascular pain in patients with pancreatic cancer. Patients receiving gemcitabine treatment should apply a hot pack to the injection site. Scrupulous clinical attention is required for patients presenting with these risk factors to improve pain management. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|